Prognostic modeling in early stage lung cancer: an evolving process from histopathology to genomics.
The goal is to validate a molecular-based tumor model that identifies patients at low-risk for cancer recurrence and who will not benefit from adjuvant chemotherapy. The remaining patients will be randomized to observation (present standard of care) or adjuvant chemotherapy to determine efficacy of adjuvant in this population. Investigators have focused on the identification of markers that may predict poor prognosis as a way to "enrich" the population by separating those likely to have early recurrence and cancer death from those not needing additional treatment after resection. The initial projects refined predictive models of cancer recurrence after resection for patients with early stage non-small cell lung cancer.
Harpole
David H
DH
Department of Surgery, Duke University Medical Center, Durham Veterans Affairs Medical Center, DUMC Box 3627, Durham, NC 27710, USA. harpo002@mc.duke.edu
D014408:Biomarkers, Tumor; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D023281:Genomics; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic
D014408:Biomarkers, Tumor